SHANGHAI, July 13, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces a favorable outcome in opposition proceedings before the European Patent Office (EPO) concerning its European...
Hence then, the article about carsgen successfully defends its gpc3 car t patent at the epo was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( CARsgen Successfully Defends Its GPC3 CAR-T Patent at the EPO )
Also on site :
- Iran’s new security boss Mohammad Zolghadr: Why his appointment matters
- Kim Jong Un uses Iran war to justify North Korea’s decision to keep its nuclear weapons
- Ventura County-Based Commercial Landscape Leader, Goldenstate Landscapes, Joins the Greater Conejo Valley Chamber of Commerce